Comparison of topical fixed-combination fortified vancomycin–amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer

Cc, Chiang; Jm, Lin; Wl, Chen; Yt, Chiu; Yy, Tsai

doi:10.1038/sj.eye.6703078

Cited by 5 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Evolving Optionsmentioning

confidence: 99%

“…A similar efficacy was observed with the two treatments, but the fixed combination provided greater convenience and tolerability and therefore facilitated patient compliance, while also avoiding the washout effect, and reducing nursing time. 101 Ophthalmological cefuroxime Data based on more than 10 years of use of intracameral cefuroxime in more than 400,000 Swedish patients reveal a very low overall incidence of POE of about 0.05% of cataract operations. [54][55][56][57] A large comparative placebo-controlled and active-controlled study was carried out by ESCRS to evaluate antibiotic prophylaxis for endophthalmitis following cataract surgery.…”

Section: Marketed Fortified Antibioticsmentioning

confidence: 99%

See 1 more Smart Citation

A European Perspective on Topical Ophthalmic Antibiotics: Current and Evolving Options

2011

View full text Add to dashboard Cite

BackgroundEye infections can be vision-threatening and must be treated effectively by appropriate and safe use of topical ophthalmic anti-infectives. This review will essentially consider the current and evolving treatment options for the various types of bacterial eye infections. Ocular surface bacterial infections affect subjects of all ages with a high frequency in newborns and children.MethodsThis article presents a review of the peer-reviewed published scientific literature in order to define the well-established uses of anti-infective eye drops in the field of ocular infections. A comprehensive search of the recent published literature including topical ophthalmic anti-infectives effective in bacterial ocular infections was performed. Clinical studies provide relevant data concerning the characteristics and clinical efficacy of antibacterial eye drops in ocular anterior segment infections or for perioperative prophylaxis. Publications were included to cover the current options of antibacterial eye drops available in Europe.ResultsSeveral recent publications identified effective topical ocular antibacterials requiring a reduced dose regimen and a short treatment course. Additional literature reviewed included data on novel perioperative prophylaxis, indications for topical fortified antibiotics and innovative research including the risk of resistance.ConclusionsSafe and effective topical antibiotic eye drops for the treatment and prevention of ocular infections must be adapted to the type of bacteria suspected. Usual topical antimicrobials should be replaced by more recent and more effective treatments. The use of highly effective fluoroquinolones should be reserved for the most severe cases to avoid resistance. Short treatment courses, such as azithromycin, can be easily used in children, thereby improving quality of life.

show abstract

Section: Evolving Optionsmentioning

confidence: 99%

Section: Marketed Fortified Antibioticsmentioning

confidence: 99%

A European Perspective on Topical Ophthalmic Antibiotics: Current and Evolving Options

2011

View full text Add to dashboard Cite

show abstract

“…1 Combined fortified vancomycin-amikacin is one of the leading options in empirical therapy for MK. 23,24 In cases of CL-related MK, ceftazidime is another option that can be used against gramnegative pathogens, as Pseudomonas spp. are among the most frequently detected agents.…”

Section: Discussionmentioning

confidence: 99%

Etiological and Clinical Features of Contact Lens-Associated Microbial Keratitis

Harbiyeli¹,

Çelebi²,

Erdem³

et al. 2022

tjo

View full text Add to dashboard Cite

Objectives: To determine the demographic, etiological, microbiological, and clinical characteristics and present treatment results of contact lens (CL)-associated microbial keratitis (CLAMK). Materials and Methods: Medical records of patients who were followed in our clinic for CLAMK between January 2014 and May 2020 were retrospectively analyzed. Demographic characteristics, symptom duration, CL and usage characteristics, risk factors, isolated microorganisms, lesion characteristics, hospital stay, recovery and follow-up times, and best corrected visual acuities (BCVA) at first and last examination were recorded. Results: The 22 patients (16 females, 6 males; 22 eyes) had a mean follow-up time of 13.0±18.3 months and mean age of 26.9±14.3 years. Most of the female patients (13/16) were under 35 years old. At least one risk factor associated with improper CL usage was identified in 21 patients (95.4%). The most common risk factor was sleeping with CL (n=15, 68.1%). Causative microorganisms were detected on microbiological examination in 15 cases (68.1%). The most common microorganism was Pseudomonas aeruginosa (n=8). Causative pathogens were sensitive at rates of 84.2%, 95% and 94.7% to combined vancomycin/amikacin, combined vancomycin/ ceftazidime, and moxifloxacin, respectively. Mean BCVA was 0.9±1.1 logMAR in the first examination and increased to 0.59±1.1 at last examination (p=0.006). There was a negative correlation between BCVA at presentation and length of hospital stay (p=0.014). Conclusion: Mistakes in CL use are a frequent predisposing factor in patients with CLAMK. Informing CL users in detail about CL usage and cleaning may reduce the frequency of these mistakes and thus infections. Current antibiotic options that should be preferred in empirical treatment remain largely effective against likely pathogens. Favorable visual outcomes can be obtained in most cases with detailed diagnostic examination and appropriate treatment approaches.

show abstract

“…These eye drops were kept at 4°C, remaining stable for at least 14 days. 27 Regarding microbiological tests, there are no clear regulatory requirements about the preparation of sterile dosage forms in community pharmacy laboratories. Current regulations are mainly applicable to the pharmaceutical industry.…”

Section: Discussionmentioning

confidence: 99%

Design and development of reinforced antibiotic eye drops in a community pharmacy

Quinteros¹,

Bessone²,

Ramirez³

et al. 2021

PPIJ

View full text Add to dashboard Cite

Objective: Develop sterile vancomycin-amikacin reinforced antibiotics in smaller batches of finished products than those produced at the industrial level and under different working conditions. In this work, critical aspects concerning the elaboration process such as equipment and process evaluation, protocol development, physicochemical characterization, and microbiological tests were analyzed. In the first stage, the preparation of the formulations was carried out in the Department of Pharmaceutical Sciences of the Faculty of Chemical Sciences of the National University of Cordoba. In the second stage, the eye drops were prepared in the laboratory of Farmacia Vilarrubi, an office pharmacy authorized by the health authority and dedicated to the preparation of non-sterile compounding formulations. Both samples prepared at different manufacturing sites were subjected to the same physicochemical and microbiological tests. Methods and results:The sample compounding formulations of Vancomycin, Amikacin or their combination, at a dose of 30 mg/mL, were developed and subjected to physicochemical essays such as macroscopic observation, measurement of pH, osmolality, particle size, and quantification of drug concentration, during 7 days stored under adequate conditions of light and temperature. In addition, microbiological assays were carried out to verify their sterility and procedure under aseptic conditions. All the formulations made of reinforced antibiotic eye drops demonstrated high physicochemical and microbiological stability during the evaluated period. Conclusion:The reinforced antibiotic eye drops and the container used for their conservation showed correct sterility and microbiological stability during the time of use for the patient. It is possible to transfer small batch production of this type of quality sterile formulations to a pharmacy. For this, the training and education of the pharmaceutical professional is imperative.

show abstract

Comparison of topical fixed-combination fortified vancomycin–amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer

Cited by 5 publications

References 17 publications

A European Perspective on Topical Ophthalmic Antibiotics: Current and Evolving Options

A European Perspective on Topical Ophthalmic Antibiotics: Current and Evolving Options

Etiological and Clinical Features of Contact Lens-Associated Microbial Keratitis

Design and development of reinforced antibiotic eye drops in a community pharmacy

Contact Info

Product

Resources

About